You are here

gene therapy

Former AveXis executives launch gene therapy startup with uncommon targets

Former AveXis executives launch gene therapy startup with uncommon targets

BioPharma Dive

Jaguar Gene Therapy

Flag link:

Precision's one-time gene editing treatment lowers cholesterol in monkeys for 3 years

Precision's one-time gene editing treatment lowers cholesterol in monkeys for 3 years

Fierce Biotech

Precision Biosciences

familial hypercholesterolemia

Flag link:

Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts

Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts

Fierce Pharma

clinical trials

Flag link:

Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

BioSpace

Charles River Labs

Cognate BioServices

Flag link:

Novartis and the Gates Foundation aim to create a more practical gene therapy for sickle cell patients around the world

Novartis and the Gates Foundation aim to create a more practical gene therapy for sickle cell patients around the world

Stat

Gates Foundation

sickle cell disease

Flag link:

Bluebird stops studies of sickle cell gene therapy after new cancer cases

Bluebird stops studies of sickle cell gene therapy after new cancer cases

BioPharma Dive

sickle cell disease

clinical trials

Flag link:

A gene therapy pipeline takes shape for a cluster of rare diseases

A gene therapy pipeline takes shape for a cluster of rare diseases

BioPharma Dive

Flag link:

Biotech entrepreneur George Church launches gene therapy startup to design safer viral vectors

Biotech entrepreneur George Church launches gene therapy startup to design safer viral vectors

Fierce Biotech

Flag link:

Bayer’s gene therapy juggling act

Bayer’s gene therapy juggling act

EP Vantage

Flag link:

Avrobio gene therapy eliminates toxic substrate in Fabry patient

Avrobio gene therapy eliminates toxic substrate in Fabry patient

Fierce Biotech

clinical trials

Flag link:

The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic

The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic

Endpoints

Vertex Pharmaceuticals

Semma Therapeutics

type 1 diabetes

Flag link:

Gene therapy for hemophilia: So close, yet so far away

Gene therapy for hemophilia: So close, yet so far away

BioPharma Dive

Flag link:

How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division

How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division

BioPharma Dive

Flag link:

Rexgenero renamed Ixaka after integration of nanoparticle tech business and funding boost

Rexgenero renamed Ixaka after integration of nanoparticle tech business and funding boost

Biopharma Reporter

Flag link:

Thermo Fisher Takes Deep Dive into Cell and Gene Therapy with Viral Vector Business Buy

Thermo Fisher Takes Deep Dive into Cell and Gene Therapy with Viral Vector Business Buy

BioSpace

Flag link:

BioMarin tries to get hemophilia gene therapy back on track with positive data

BioMarin tries to get hemophilia gene therapy back on track with positive data

BioPharma Dive

clinical trials

Flag link:

Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial

Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial

BioPharma Dive

Sarepta Therapeutics

clinical trials

Duchenne Muscular Dystrophy

Flag link:

Biotech Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio

Biotech Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio

Fierce Biotech

venture capital

Senti Biosciences

Flag link:

Fujifilm's CDMO carves foothold in Boston biotech hub with new HQ focused on viral vectors, gene therapies

Fujifilm's CDMO carves foothold in Boston biotech hub with new HQ focused on viral vectors, gene therapies

Endpoints

Fujifilm Diosynth Biotechnologies

Flag link:

Audentes sees FDA hold lifted after 3 trial deaths blighted $3B program

Audentes sees FDA hold lifted after 3 trial deaths blighted $3B program

Fierce Biotech

clinical trials

X-linked myotubular myopathy

Flag link:

Pages